SINOPHARM TECH (08156) disclosed the monthly return for the period ended 28 February 2026. The total authorized share capital stood at 200.00 million HKD, comprising 12.80 billion ordinary shares at a par value of 0.0125 HKD each (160.00 million HKD) and 3.20 billion non-voting convertible preference shares at the same par value (40.00 million HKD).

As of 28 February 2026, the company reported 633.69 million issued ordinary shares with no changes during the month. The issued convertible preference shares, totaling 1.48 billion, also remained unchanged. The public float requirement of 25% was confirmed to be met.

Regarding share options under the 2021 Share Option Scheme, 5.28 million were outstanding at the end of the preceding month. During February, 0.20 million lapsed, leaving 5.08 million outstanding with no new shares issued. No conversions of preference shares or other share movements were recorded for this period.